Clinical trials | EDC - IRCCS - Istituto Nazionale dei Tumori

INFO & CONTACTS: +39 02 2390 1

Search

Search

Follow us on

Clinical trials

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1

Drug: Arm A: MK-2870
Arm B: MK-2870+Pembrolizumab
Arm C: Paclitaxel/ Nab-Paclitaxel/ Capecitabine/ Liposomal Doxorubicin
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Part

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Pembrolizumab
Sacituzumab govitecan (SG).
An International, Phase 3, Randomized, Multicenter, Openlabel Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Muta

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 2

Drug: Ripretinib VS Sunitinib
A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) p

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: Avelumab, Cetuximab
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomi

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: MK2870 (sacituzumab tirumotecan)
Docetaxel
Pemetrexed
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: MK-2870 (sacituzumab tirumotecan)
Pembrolizumab
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with pr

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Belrestotug
Dostarlimab
Pembrolizumab
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate GSK4057190A as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: GSK4057190A
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 2

Drug: INBRX-109 / Placebo
A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High-Risk RetroPeritoneal Sarcoma (STRASS 2)

Phase: Phase II-III clinical trials

Principal Investigator: Dr. Gronchi Alessandro

Main Facility: General Surgery 7 – Sarcomas

Drug: For high-risk Dedifferentiated Liposarcoma (DDLPS): Doxorubicin + Ifosfamide.
For Leiomyosarcoma (LMS): Doxorubicin + Dacarbazine.
A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Rusconi Chiara

Main Facility: Ematologia

Drug: Ruxolitinib
A Phase IIIb, Randomized, Multicenter, Open-Label Study of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-Stage Hepatocellular Carcinoma

Phase: Phase II-III clinical trials

Main Facility: Oncologic Surgery 1 – Hepato-Gastro-Pancreatic and Liver Transplantation

Drug: Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE)
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of MEDI5752 as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Pr

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: MEDI5752
A phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a cdk4/6 inhibitor, in patients with estrogen receptor-positive, her2-negative advanc

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1

Drug: Giredestrant + inibitore di CDK4/6
Fulvestrant + inibitore di CDK4/6
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced o

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Savolitinib
Osimertinib
Chemotherapy (Pemetrexed + carboplatin or Pemetrexed + Cisplatin)
A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of inavolisib in combination with phesgo versus placebo in combination with phesgo as maintenance therapy af

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1

Drug: RO7198574 + Inavolisib
RO7198574 + Placebo
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non–Small Cell Lung Cancer

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Zimberelimab, Domvanalimab, Quemliclustat, Chemotherapy
A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Volrustomig
Chemotherapy (Carboplatin an Pemetrexed)
A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: KTE-X-19 (brexucabtagene autoleucel)
A phase Ib/II, open-label, multicentric study evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metas

Phase: Phase II-III clinical trials

Principal Investigator: Prof. De Braud Filippo

Main Facility: Thoracic Oncology Unit

Drug: Divarasib, Pembrolizumab, Chemotherapy